Erdogan cancels visit to Kazakhstan due to Istanbul terrorist attack - newspaperWorld December 11, 11:15
The deal of buying Rosneft's 19.5% stock is outside sanctions - sourceBusiness & Economy December 11, 11:12
Syrian military supported by the Russian aircraft repel IS attacks near PalmyraWorld December 11, 11:10
Five people die in fire in Tatarstan-emergencies ministrySociety & Culture December 11, 11:04
Turkey declares one day of national mourning over Istanbul terrorist attackWorld December 11, 7:10
Turkish authorities impose media ban on coverage of Istanbul explosionWorld December 11, 3:01
Erdogan says Istanbul terrorist attack causes fatalitiesWorld December 11, 2:52
Istanbul explosions leave 15 dead, 69 wounded — TV channelWorld December 11, 2:38
Three settlements in Syria join cessation of hostilities — Russia’s Defense MinistryWorld December 11, 2:34
GENEVA, June 14. /TASS/. The Court of Arbitration for Sport announced on Tuesday that it would announce its decision regarding an appeal from Russian tennis player Maria Sharapova before July 18.
According to various media reports earlier in the day, tennis star Sharapova has filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
"In her appeal to the CAS, Ms Sharapova seeks the annulment of the Tribunal’s decision to sanction her with a two-year period of ineligibility further to an anti-doping rule violation," the CAS said in its statement. "Ms Sharapova submits that the period of ineligibility should be eliminated, or in the alternative, reduced."
"The parties have agreed to an expedited procedure which will allow the CAS to render a decision, at the latest, on 18 July 2016," the statement added.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.